CMV-specific immune reconstitution following allogeneic stem cell transplantation

References

• Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am 2011; 25:151-69; http://dx.doi.org/10.1016/j.hoc.2010.11.011
   PubMed Web of Science ®Google Scholar
• Thiele T, Krüger W, Zimmermann K, Ittermann T, Wessel A, Steinmetz I, Dölken G, Greinacher A. Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME). Transfusion 2011; 51:2620-6; PMID:21645009; http://dx.doi.org/10.1111/j.1537-2995.2011.03203.x
   PubMed Web of Science ®Google Scholar
• Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 2004; 4:725-38; PMID:15567122; http://dx.doi.org/10.1016/S1473-3099(04)01202-2
   PubMed Web of Science ®Google Scholar
• Boeckh MJ, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, Stevens-Ayers T, Flowers ME, Cunningham T, Corey L. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003; 101:407-14; PMID:12393659; http://dx.doi.org/10.1182/blood-2002-03-0993
   PubMed Web of Science ®Google Scholar
• Ozdemir E, Saliba RM, Champlin RE, Couriel DR, Giralt SA, de Lima M, Khouri IF, Hosing C, Kornblau SM, Anderlini P, et al. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplantation 2007; 40:125-36; PMID:17530009; http://dx.doi.org/10.1038/sj.bmt.1705699
   PubMed Web of Science ®Google Scholar
• Nguyen Q, Champlin R, Giralt S, Rolston K, Raad I, Jacobson K, Ippoliti C, Hecht D, Tarrand J, Luna M, et al. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin Infect Dis 1999; 28:618-23; PMID:10194088; http://dx.doi.org/10.1086/515146
   PubMed Web of Science ®Google Scholar
• Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, Ebeling DF, Buhles WC, DeArmond B, Meyers JD. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Eng J Med 1991; 325:1601-7; PMID:1658652; http://dx.doi.org/10.1056/NEJM199112053252303
   PubMed Web of Science ®Google Scholar
• Green ML, Leisenring W, Stachel D, Pergam SA, Sandmaier BM, Wald A, Corey L, Boeckh MJ. Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of Cytomegalovirus disease after hematopoietic cell transplantation. Biol Blood Marrow Transplantation 2012; 18:1687-99; PMID:22683614; http://dx.doi.org/10.1016/j.bbmt.2012.05.015
   PubMed Web of Science ®Google Scholar
• Erice A, Gil-Roda C, Pérez JL, Balfour HH, Sannerud KJ, Hanson MN, Boivin G, Chou S. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis 1997; 175:1087-92; PMID:9129070; http://dx.doi.org/10.1086/516446
   PubMed Web of Science ®Google Scholar
• Herling M, Schröder L, Awerkiew S, Chakupurakal G, Holtick U, Kaiser R, Pfister H, Scheid C, Di Cristanziano V. Persistent CMV infection after allogeneic hematopoietic stem cell transplantation in a CMV-seronegative donor-to-positive recipient constellation: Development of multidrug resistance in the absence of anti-viral cellular immunity. J Clin Virol 2016; 74:57-60; PMID:26672492; http://dx.doi.org/10.1016/j.jcv.2015.11.033
   PubMed Web of Science ®Google Scholar
• Paul S, Dummer S. Topics in clinical pharmacology: ganciclovir. Am J Med Sci 1992; 304:272-7; PMID:1329509; http://dx.doi.org/10.1097/00000441-199210000-00010
   PubMed Web of Science ®Google Scholar
• Jain NA, Lu K, Ito S, Muranski P, Hourigan CS, Haggerty J, Chokshi PD, Ramos C, Cho E, Cook L, et al. The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation—implications for preventative treatment approaches. Cytotherapy 2014; 16:927-33; PMID:24831837; http://dx.doi.org/10.1016/j.jcyt.2014.02.010
   PubMed Web of Science ®Google Scholar
• Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Eng J Med 1991; 324:1005-11; PMID:1848679; http://dx.doi.org/10.1056/NEJM199104113241501
   PubMed Web of Science ®Google Scholar
• Konoplev S, Champlin RE, Giralt S, Ueno NT, Khouri I, Raad I, Rolston K, Jacobson K, Tarrand J, Luna M, et al. Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients. Bone Marrow Transplantation 2001; 27:877-81; PMID:11477447; http://dx.doi.org/10.1038/sj.bmt.1702877
   PubMed Web of Science ®Google Scholar
• Green ML, Leisenring W, Xie H, Mast TC, Cui Y, Sandmaier BM, Sorror ML, Goyal S, Ozkok S, Yi J, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol 2016; 3(3):e119-27: 1–9
   PubMed Web of Science ®Google Scholar
• Broers AE, van Der Holt R, van Esser JW, Gratama JW, Henzen-Logmans S, Kuenen-Boumeester V, Löwenberg B, Cornelissen JJ. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 2000; 95:2240-5; PMID:10733491
   PubMed Web of Science ®Google Scholar
• Craddock C, Szydlo RM, Dazzi F, Olavarria E, Cwynarski K, Yong A, Brookes P, de la Fuente J, Kanfer E, Apperley JF, et al. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. Br J Haematol 2001; 112:228-36; PMID:11167809; http://dx.doi.org/10.1046/j.1365-2141.2001.02519.x
   PubMed Web of Science ®Google Scholar
• Boeckh MJ, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004; 103:2003-8; PMID:14644993; http://dx.doi.org/10.1182/blood-2003-10-3616
   PubMed Web of Science ®Google Scholar
• Teira P, Battiwalla M, Ramanathan M, Barrett AJ, Ahn KW, Chen M, Green JS, Saad A, Antin JH, Savani BN, et al. Early cytomegalovirus reactivation remains associated with increased transplant related mortality in the current era: a CIBMTR analysis. Blood 2016; 127(20):2427-38: blood-2015-11-679639-41
   PubMed Web of Science ®Google Scholar
• Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 2003; 102:4255-60; PMID:12933590; http://dx.doi.org/10.1182/blood-2002-10-3263
   PubMed Web of Science ®Google Scholar
• Ljungman P, Brand R, Hoek J, de la Cámara R, Cordonnier C, Einsele H, Styczynski J, Ward KN, Cesaro S. Transplantation IDWPotEGfBaM. Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation. Clin Infect Dis 2014; 59:473-81; PMID:24850801; http://dx.doi.org/10.1093/cid/ciu364
   PubMed Web of Science ®Google Scholar
• Schmidt-Hieber M, Labopin M, Beelen D, Volin L, Ehninger G, Finke J, Socie G, Schwerdtfeger R, Kröger N, Ganser A, et al. CMV serostatus has still an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. Blood 2013; 122(19):3359-64; PMID:24037724
   PubMed Web of Science ®Google Scholar
• Marty FM, Winston DJ, Rowley SD, Vance E, Papanicolaou GA, Mullane KM, Brundage TM, Robertson AT, Godkin S, Momméja-Marin H, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Eng J Med 2013; 369:1227-36; PMID:24066743; http://dx.doi.org/10.1056/NEJMoa1303688
   PubMed Web of Science ®Google Scholar
• Marty FM, Ljungman P, Papanicolaou GA, Winston DJ, Chemaly RF, Strasfeld L, Young JA, Rodriguez T, Maertens J, Schmitt M, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 2011; 11:284-92; PMID:21414843; http://dx.doi.org/10.1016/S1473-3099(11)70024-X
   PubMed Web of Science ®Google Scholar
• Chemaly RF, Ullmann AJ, Stoelben S, Richard MP, Bornhäuser M, Groth C, Einsele H, Silverman M, Mullane KM, Brown J, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Eng J Med 2014; 370:1781-9; PMID:24806159; http://dx.doi.org/10.1056/NEJMoa1309533
   PubMed Web of Science ®Google Scholar
• Boppana SB, Britt WJ. Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J Infect Dis 1995; 171:1115-21; PMID:7751685; http://dx.doi.org/10.1093/infdis/171.5.1115
   PubMed Web of Science ®Google Scholar
• Nigro G, Adler SP, La Torre R, Best AM, Group CC. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Eng J Med 2005; 353:1350-62; PMID:16192480; http://dx.doi.org/10.1056/NEJMoa043337
   PubMed Web of Science ®Google Scholar
• Schoppel K, Schmidt C, Einsele H, Hebart H, Mach M. Kinetics of the antibody response against human cytomegalovirus-specific proteins in allogeneic bone marrow transplant recipients. J Infect Dis 1998; 178:1233-43; PMID:9780241; http://dx.doi.org/10.1086/314428
   PubMed Web of Science ®Google Scholar
• Volpi A, Pica F, Gentile G, Capobianchi A, Fraschetti M, Martino P. Neutralizing antibody response against human cytomegalovirus in allogeneic bone marrow-transplant recipients. J Infect Dis 1999; 180:1747-8; PMID:10515847; http://dx.doi.org/10.1086/315092
   PubMed Web of Science ®Google Scholar
• Adler SP, Nigro G. Findings and conclusions from CMV hyperimmune globulin treatment trials. J Clin Virol 2009; 46:S54-7; PMID:19781985; http://dx.doi.org/10.1016/j.jcv.2009.08.017
   PubMed Web of Science ®Google Scholar
• Maidji E, Nigro G, Tabata T, McDonagh S, Nozawa N, Shiboski S, Muci S, Anceschi MM, Aziz N, Adler SP, et al. Antibody treatment promotes compensation for human cytomegalovirus-induced pathogenesis and a hypoxia-like condition in placentas with congenital infection. Am J Pathol 2010; 177:1298-310; PMID:20651234; http://dx.doi.org/10.2353/ajpath.2010.091210
   PubMed Web of Science ®Google Scholar
• Jacobsen N, Schäfer U, Ostendorf P, Kubaneck B, Wolf H. Intravenous hyperimmune globulin prophylaxis against cytomegalovirus interstitial pneumonitis after allogenic bone marrow transplantation. Tokai J Exp Clin Med 1985; 10:193-5; PMID:3010510
   PubMedGoogle Scholar
• Yust I, Fox Z, Burke M, Johnson A, Turner D, Mocroft A, Katlama C, Ledergerber B, Reiss P, Kirk O, et al. Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe: a EuroSIDA study, 1994-2001. Eur J Clin Microbiol Infect 2004; 23:550-9
   PubMed Web of Science ®Google Scholar
• Montillo M, Tedeschi A, Petrizzi VB, Ricci F, Crugnola M, Spriano M, Spedini P, Ilariucci F, Uziel L, Attolico I, et al. An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia. Blood 2011; 118:4079-85; PMID:21772050; http://dx.doi.org/10.1182/blood-2011-05-351833
   PubMed Web of Science ®Google Scholar
• Grigg A, Chapman R, Szer J. Fatal CMV pneumonia associated with steroid therapy after autologous transplantation in patients previously treated with fludarabine. Bone Marrow Transplantation 1998; 21:619-21; PMID:9543067; http://dx.doi.org/10.1038/sj.bmt.1701126
   PubMed Web of Science ®Google Scholar
• Orlandi EM, Baldanti F, Citro A, Pochintesta L, Gatti M, Lazzarino M. Monitoring for cytomegalovirus and Epstein-Barr virus infection in chronic lymphocytic leukemia patients receiving i.v. fludarabine-cyclophosphamide combination and alemtuzumab as consolidation therapy. Haematologica 2008; 93:1758-60; PMID:18790800; http://dx.doi.org/10.3324/haematol.13265
   PubMed Web of Science ®Google Scholar
• Berger C, Berger M, Anderson D, Riddell SR. A non-human primate model for analysis of safety, persistence, and function of adoptively transferred T cells. J Medical Primatol 2011; 40:88-103; http://dx.doi.org/10.1111/j.1600-0684.2010.00451.x
   PubMed Web of Science ®Google Scholar
• Wang X, Berger C, Wong CW, Forman SJ, Riddell SR, Jensen MC. Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. Blood 2011; 117:1888-98; PMID:21123821; http://dx.doi.org/10.1182/blood-2010-10-310599
   PubMed Web of Science ®Google Scholar
• Riddell SR, Greenberg P. Therapeutic reconstitution of human viral immunity by adoptive transfer of cytotoxic T lymphocyte clones. Curr Topics Microbiol Immunol 1994; 189:9-34; PMID:7924439
   PubMedGoogle Scholar
• Micklethwaite KP, Hansen A, Foster AE, Snape E, Antonenas V, Sartor M, Shaw P, Bradstock K, Gottlieb DJ. Ex-Vivo expansion and Prophylactic infusion of CMV-pp65 peptide specific cytotoxic T-Lymphocytes following allogeneic haemopoietic stem cell transplantation. Biol Blood Marrow Transplantation 2007; 13:707-14; PMID:17531781; http://dx.doi.org/10.1016/j.bbmt.2007.02.004
   PubMed Web of Science ®Google Scholar
• Micklethwaite KP, Clancy L, Sandher U, Hansen A, Blyth E, Antonenas V, Sartor M, Bradstock K, Gottlieb DJ. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood 2008; 112:3974; PMID:18768783; http://dx.doi.org/10.1182/blood-2008-06-161695
   PubMed Web of Science ®Google Scholar
• Rooney CM, Smith C, Ng CY, Loftin SK, Sixbey JW, Gan Y, Srivastava DK, Bowman LC, Krance RA, Brenner MK, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92:1549-55; PMID:9716582
   PubMed Web of Science ®Google Scholar
• Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, Carrum G, Krance RA, Chang CC, Molldrem JJ, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006; 12:1160-6; PMID:16998485; http://dx.doi.org/10.1038/nm1475
   PubMed Web of Science ®Google Scholar
• Peggs KS, Thomson K, Samuel E, Dyer G, Armoogum J, Chakraverty R, Pang K, Mackinnon S, Lowdell MW. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis 2011; 52:49-57; PMID:21148519; http://dx.doi.org/10.1093/cid/ciq042
   PubMed Web of Science ®Google Scholar
• Peggs KS. Adoptive T cell immunotherapy for cytomegalovirus. Exp Opin Biol Therapy 2009; 9:725-36; PMID:19456207; http://dx.doi.org/10.1517/14712590902967588
   PubMed Web of Science ®Google Scholar
• Blyth E, Clancy L, Simms R, Ma CK, Burgess J, Deo S, Byth K, Dubosq M-C, Shaw PJ, Micklethwaite KP, et al. Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood 2013; 121:3745-58; PMID:23435462; http://dx.doi.org/10.1182/blood-2012-08-448977
   PubMed Web of Science ®Google Scholar
• Clancy L, Blyth E, Simms R, Micklethwaite KP, Ma CK, Burgess J, Antonenas V, Shaw P, Gottlieb DJ. CMV-specific cytotoxic T lymphocytes can be efficiently expanded from G-CSF mobilised haemopoietic progenitor cell products ex vivo and safely transferred to stem cell transplant recipients to facilitate immune reconstitution. Biol Blood Marrow Transplantation 2013; 19(5): 725-734.
   PubMed Web of Science ®Google Scholar
• Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, Sleath PR, Grabstein KH, Hosken NA, Kern F, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005; 202:673-85; PMID:16147978; http://dx.doi.org/10.1084/jem.20050882
   PubMed Web of Science ®Google Scholar
• Wills MR, Okecha G, Weekes MP, Gandhi MK, Sissons PJ, Carmichael AJ. Identification of naive or antigen-experienced human CD8(+) T cells by expression of costimulation and chemokine receptors: analysis of the human cytomegalovirus-specific CD8(+) T cell response. J Immunol 2002; 168:5455-64; PMID:12023339; http://dx.doi.org/10.4049/jimmunol.168.11.5455
   PubMed Web of Science ®Google Scholar
• Maecker H, Maino V. Analyzing t-cell responses to cytomegalovirus by cytokine flow cytometry. Human Immunology 2004; 65:493-9; PMID:15172449; http://dx.doi.org/10.1016/j.humimm.2004.02.004
   PubMed Web of Science ®Google Scholar
• Wills MR, Carmichael AJ, Mynard K, Jin X, Weekes MP, Plachter B, Sissons JG. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 1996; 70:7569-79; PMID:8892876
   PubMed Web of Science ®Google Scholar
• Beninga J, Kropff B, Mach M. Comparative analysis of fourteen individual human cytomegalovirus proteins for helper T cell response. J General Virol 1995; 76:153-60; PMID:7844526; http://dx.doi.org/10.1099/0022-1317-76-1-153
   PubMed Web of Science ®Google Scholar
• Beninga J, Kalbacher H, Mach M. Analysis of T helper cell response to glycoprotein H (gpUL75) of human cytomegalovirus: evidence for strain-specific T cell determinants. J Infect Dis 1996; 173:1051-61; PMID:8627054; http://dx.doi.org/10.1093/infdis/173.5.1051
   PubMed Web of Science ®Google Scholar
• Sund F, Lidehäll A-K, Claesson K, Foss A, Tötterman TH, Korsgren O, Eriksson BM. CMV-specific T-cell immunity, viral load, and clinical outcome in seropositive renal transplant recipients: a pilot study. Clin Transplantation 2010; 24:401-9; PMID:19222507; http://dx.doi.org/10.1111/j.1399-0012.2009.00976.x
   PubMed Web of Science ®Google Scholar
• Gamadia LE, Rentenaar RJ, Baars PA, Remmerswaal EB, Surachno S, Weel JF, Toebes M, Schumacher TN, ten Berge IJ, van Lier RA. Differentiation of cytomegalovirus-specific CD8(+) T cells in healthy and immunosuppressed virus carriers. Blood 2001; 98:754-61; PMID:11468176; http://dx.doi.org/10.1182/blood.V98.3.754
   PubMed Web of Science ®Google Scholar
• Gamadia LE, Remmerswaal EB, WeelJF, Bemelman F, van Lier RA, ten Berge IJ. Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood 2003; 101:2686-92; PMID:12411292; http://dx.doi.org/10.1182/blood-2002-08-2502
   PubMed Web of Science ®Google Scholar
• Lilleri D, Gerna G, Zelini P, Chiesa A, Rognoni V, Mastronuzzi A, Giorgiani G, Zecca M, Locatelli F. Monitoring of human cytomegalovirus and virus-specific T-cell response in young patients receiving allogeneic hematopoietic stem cell transplantation. PloS One 2012; 7:e41648; PMID:22848556; http://dx.doi.org/10.1371/journal.pone.0041648
   PubMed Web of Science ®Google Scholar
• Riddell SR, Walter BA, Gilbert MJ, Greenberg PD. Selective reconstitution of CD8+ cytotoxic T lymphocyte responses in immunodeficient bone marrow transplant recipients by the adoptive transfer of T cell clones. Bone Marrow Transplantation 1994; 14:S78-84; PMID:7728132
   PubMedGoogle Scholar
• Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Loffler J, Grigoleit GU, Moris A, Rammensee H-G, Kanz L, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99:3916-22; PMID:12010789; http://dx.doi.org/10.1182/blood.V99.11.3916
   PubMed Web of Science ®Google Scholar
• Ganepola S, Gentilini C, Hilbers U, Lange T, Rieger K, Hofmann J, Maier M, Liebert UG, Niederwieser D, Engelmann E, et al. Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation. Bone Marrow Transplantation 2007; 39:293-9; PMID:17262060; http://dx.doi.org/10.1038/sj.bmt.1705585
   PubMed Web of Science ®Google Scholar
• Tormo N, Solano C, Benet I, Clari MA, Nieto J, de la Camara R, López J, López-Aldeguer N, Hernández-Boluda JC, Remigia MJ, et al. Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplantation 2010; 45:543-9; PMID:19617905; http://dx.doi.org/10.1038/bmt.2009.172
   PubMed Web of Science ®Google Scholar
• Tormo N, Solano C, Benet I, Nieto J, de la Cámara R, Garcia-Noblejas A, Clari MÁ, Chilet M, López J, Hernández-Boluda JC, et al. Kinetics of cytomegalovirus (CMV) pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells during episodes of viral DNAemia in allogeneic stem cell transplant recipients: potential implications for the management of active CMV infection. J Medical Virol 2010; 82:1208-15; PMID:20513086; http://dx.doi.org/10.1002/jmv.21799
   PubMed Web of Science ®Google Scholar
• Scheinberg P, Melenhorst JJ, Brenchley JM, Hill BJ, Hensel NF, Chattopadhyay PK, Roederer M, Picker LJ, Price DA, Barrett AJ, et al. The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donor. Blood 2009; 114:5071-80; PMID:19776383; http://dx.doi.org/10.1182/blood-2009-04-214684
   PubMed Web of Science ®Google Scholar
• Luo XH, Huang XJ, Liu KY, Xu LP, Liu DH. Protective immunity transferred by infusion of CMV-specific CD8+ T cells within donor graftsits associations with CMV reactivation following unmanipulated allogeneic hematopoietic stem cell transplantation CMV-specific CD8+ T cells within donor grafts. Biol Blood Marrow Transplantation 2010; 16(7):994-1004
   PubMed Web of Science ®Google Scholar
• Winston DJ, Huang ES, Miller MJ, Lin CH, Ho WG, Gale RP, Champlin RE. Molecular epidemiology of cytomegalovirus infections associated with bone marrow transplantation. Annals Internal Med 1985; 102:16-20; PMID:2981496; http://dx.doi.org/10.7326/0003-4819-102-1-16
   PubMed Web of Science ®Google Scholar
• Gandhi MK, Wills MR, Okecha G, Day EK, Hicks R, Marcus RE, Sissons JG, Carmichael AJ. Late diversification in the clonal composition of human cytomegalovirus-specific CD8+ T cells following allogeneic hemopoietic stem cell transplantation. Blood 2003; 102:3427-38; PMID:12869514; http://dx.doi.org/10.1182/blood-2002-12-3689
   PubMed Web of Science ®Google Scholar
• Gandhi MK, Wills MR, Sissons JG, Carmichael AJ. Human cytomegalovirus-specific immunity following haemopoietic stem cell transplantation. Blood Rev 2003; 17:259-64; PMID:14556781; http://dx.doi.org/10.1016/S0268-960X(03)00028-6
   PubMed Web of Science ®Google Scholar
• Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: Evidence for indirect effects of primary CMV infection. J Infect Dis 2002; 185:273-82; PMID:11807708; http://dx.doi.org/10.1086/338624
   PubMed Web of Science ®Google Scholar
• Ljungman P, Aschan J, Lewensohn-Fuchs I, Carlens S, Larsson K, Lonnqvist B, Mattsson J, Sparrelid E, Winiarski J, Ringden O. Results of different strategies for reducing: Cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation 1998; 66:1330-4; PMID:9846518; http://dx.doi.org/10.1097/00007890-199811270-00012
   PubMed Web of Science ®Google Scholar
• Broers AE, van Der Holt R, van Esser JW, Gratama JW, Henzen-Logmans S, Kuenen-Boumeester V, Lowenberg B, Cornelissen JJ. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 2000; 95:2240-5; PMID:10733491
   PubMed Web of Science ®Google Scholar
• Sellar RS, Vargas FA, Henry JY, Verfuerth S, Charrot S, Beaton B, Chakraverty R, Quezada SA, Mackinnon S, Thomson KJ, et al. CMV promotes recipient T-cell immunity following reduced-intensity T-cell-depleted HSCT, significantly modulating chimerism status. Blood 2015; 125:731-9; PMID:25499763; http://dx.doi.org/10.1182/blood-2014-07-589150
   PubMed Web of Science ®Google Scholar
• Stevanović S, van Bergen CA, van Luxemburg-Heijs SA, van der Zouwen B, Jordanova ES, Kruisselbrink AB, van de Meent M, Harskamp JC, Claas FH, Marijt EW, et al. HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+ donor lymphocyte infusion. Blood 2013; 122:1963-73; PMID:23777765; http://dx.doi.org/10.1182/blood-2012-12-470872
   PubMed Web of Science ®Google Scholar
• Oliveira G, Ruggiero E, Stanghellini MT, Cieri N, D'Agostino M, Fronza R, Lulay C, Dionisio F, Mastaglio S, Greco R, et al. Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory. Sci Translational Med 2015; 7:317ra198; PMID:26659572
   PubMed Web of Science ®Google Scholar
• Link CS, Eugster A, Heidenreich F, Rücker-Braun E, Schmiedgen M, Oelschlägel U, Kühn D, Dietz S, Fuchs Y, Dahl A, et al. Abundant CMV reactive clonotypes in the CD8(+) T cell receptor α repertoire following allogeneic transplantation. Clin Exp Immunol 2016; 184(3):389-402: n/a-n/a; PMID:26800118
   PubMed Web of Science ®Google Scholar
• Suessmuth Y, Mukherjee R, Watkins B, Koura DT, Finstermeier K, Desmarais C, Stempora L, Horan JT, Langston A, Qayed M, et al. CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRβ repertoire. Blood 2015; 125:3835-50; PMID:25852054; http://dx.doi.org/10.1182/blood-2015-03-631853
   PubMed Web of Science ®Google Scholar
• Itzykson R, Robin M, Moins-Teisserenc H, Delord M, Busson M, Xhaard A, de Fontebrune FS, Peffault de Latour R, Toubert A, Socie G. Cytomegalovirus shapes long-term immune reconstitution after allogeneic stem cell transplantation. Haematologica 2015; 100:114-23; PMID:25261095; http://dx.doi.org/10.3324/haematol.2014.113415
   PubMed Web of Science ®Google Scholar
• Knight A, Madrigal AJ, Grace S, Sivakumaran J, Kottaridis P, Mackinnon S, Travers PJ, Lowdell MW. The role of Vδ2-negative γδ T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation. Blood 2010; 116:2164-72; PMID:20576814; http://dx.doi.org/10.1182/blood-2010-01-255166
   PubMed Web of Science ®Google Scholar
• Storek J. Immunological reconstitution after hematopoietic cell transplantation - its relation to the contents of the graft. Exp Opin Biol Therapy 2008; 8:583-97; PMID:18407763; http://dx.doi.org/10.1517/14712598.8.5.583
   PubMed Web of Science ®Google Scholar
• Foley B, Cooley S, Verneris MR, Pitt M, Curtsinger J, Luo X, Lopez-Vergès S, Lanier LL, Weisdorf D, Miller JS. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood 2012; 119:2665-74; PMID:22180440; http://dx.doi.org/10.1182/blood-2011-10-386995
   PubMed Web of Science ®Google Scholar
• Muñoz-Cobo B, Solano C, Benet I, Costa E, Remigia MJ, de la Cámara R, Nieto J, López J, Amat P, Garcia-Noblejas A, et al. Functional profile of cytomegalovirus (CMV)-specific CD8+ T cells and kinetics of NKG2C+ NK cells associated with the resolution of CMV DNAemia in allogeneic stem cell transplant recipients. J Medical Virol 2012; 84:259-67; http://dx.doi.org/10.1002/jmv.22254
   PubMed Web of Science ®Google Scholar
• Schabert VF, Mozaffari E, Lee YC, Casciano R. Double-stranded DNA (dsDNA) viral infections among allogeneic hematopoietic cell transplant (HCT) recipients in the first year after transplant. Blood 2015; 126:3296
   Google Scholar
• Huang Y-TH, Kim SJ, Lee YJ, Burack D, Nichols P, Maloy M, Tamari R, Perales MA, Giralt SA, Castro-Malaspina HR, et al. Infection burden of double stranded DNA (dsDNA) viruses after CD34+ selected, T-Cell depleted (TCD) hematopoietic cell transplantation (HCT) for myeloid malignancies at memorial sloan kettering cancer center (MSK). Blood 2015; 126:4320; http://dx.doi.org/10.1182/blood-2015-05-646687
   Web of Science ®Google Scholar
• Mozaffari E, Lin J, Lingohr-Smith M. Hospitalizations and mortality associated with dsDNA viral infections among hematopoietic cell transplant recipients. Blood 2015; 126:2073
   Web of Science ®Google Scholar
• Hill JA, Mayer BT, Xie H, Leisenring WM, Milano F, Delaney C, Huang ML, Stevens-Ayers TL, Jerome KR, Nichols G, et al. Detection of multiple Double-Stranded DNA viruses after cord blood transplantation is frequent and persistent. Blood 2015; 126:3104
   Web of Science ®Google Scholar
• Noviello M, Forcina A, Veronica V, Crocchiolo R, Stanghellini MT, Carrabba M, Greco R, Vago L, Giglio F, Assanelli A, et al. Early recovery of CMV immunity after HLA-haploidentical hematopoietic stem cell transplantation as a surrogate biomarker for a reduced risk of severe infections overall. Bone Marrow Transplantation 2015; 50:1262-4; PMID:26076126; http://dx.doi.org/10.1038/bmt.2015.132
   PubMed Web of Science ®Google Scholar
• Bravo D, Solano C, Giménez E, Remigia MJ, Corrales I, Amat P, Navarro D. Effect of the IL28B Rs12979860 C/T polymorphism on the incidence and features of active cytomegalovirus infection in allogeneic stem cell transplant patients. J Medical Virol 2014; 86:838-44; PMID:24374819; http://dx.doi.org/10.1002/jmv.23865
   PubMed Web of Science ®Google Scholar
• Corrales I, Giménez E, Solano C, Amat P, de la Cámara R, Nieto J, Garcia-Noblejas A, Navarro D. Incidence and dynamics of active cytomegalovirus infection in allogeneic stem cell transplant patients according to single nucleotide polymorphisms in donor and recipient CCR5, MCP-1, IL-10, and TLR9 genes. J Medical Virol 2015; 87:248-55; PMID:25132583; http://dx.doi.org/10.1002/jmv.24050
   PubMed Web of Science ®Google Scholar
• Mezger M, Steffens M, Semmler C, Arlt E-M, Zimmer M, Kristjanson G-I, Wienker TF, Toliat MR, Kessler T, Einsele H, et al. Investigation of promoter variations in dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN) (CD209) and their relevance for human cytomegalovirus reactivation and disease after allogeneic stem-cell transplantation. Clin Microbiol Infect 2008; 14:228-34; PMID:18076668; http://dx.doi.org/10.1111/j.1469-0691.2007.01902.x
   PubMed Web of Science ®Google Scholar
• Xiao HW, Luo Y, Lai XY, Shi JM, Tan YM, He JS, Xie WZ, Zheng WY, Ye XJ, Yu XH, et al. Donor TLR9 gene tagSNPs influence susceptibility to aGVHD and CMV reactivation in the allo-HSCT setting without polymorphisms in the TLR4 and NOD2 genes. Bone Marrow Transplantation 2014; 49:241-7; PMID:24121213; http://dx.doi.org/10.1038/bmt.2013.160
   PubMed Web of Science ®Google Scholar
• Ozdemir E, St John LS, Gillespie G, Rowland-Jones S, Champlin RE, Molldrem JJ, Komanduri KV. Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. Blood 2002; 100:3690-7; PMID:12393402; http://dx.doi.org/10.1182/blood-2002-05-1387
   PubMed Web of Science ®Google Scholar
• Guerrero A, Riddell SR, Storek J, Stevens-Ayers T, Storer B, Zaia JA, Forman S, Negrin RS, Chauncey T, Bensinger W, et al. Cytomegalovirus viral load and virus-specific immune reconstitution after peripheral blood stem cell versus bone marrow transplantation. Biol Blood Marrow Transplantation 2012; 18:66-75; PMID:21664286; http://dx.doi.org/10.1016/j.bbmt.2011.05.010
   PubMed Web of Science ®Google Scholar
• Morita-Hoshi Y, Heike Y, Kawakami M, Sugita T, Miura O, Kim S-W, Mori S-I, Fukuda T, Tanosaki R, Tobinai K, et al. Functional analysis of cytomegalovirus-specific T lymphocytes compared to tetramer assay in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplantation 2008; 41:515-21; PMID:18026143; http://dx.doi.org/10.1038/sj.bmt.1705932
   PubMed Web of Science ®Google Scholar
• Gimenez E, Muñoz-Cobo B, Solano C, Amat P, de la Camara R, Nieto J, López J, Remigia MJ, Garcia-Noblejas A, Navarro D. Functional patterns of cytomegalovirus (CMV) pp65 and immediate early-1-specific CD8(+) T cells that are associated with protection from and control of CMV DNAemia after allogeneic stem cell transplantation. Transplant Infect Dis 2015; 17:361-70; PMID:25850900; http://dx.doi.org/10.1111/tid.12391
   PubMed Web of Science ®Google Scholar
• Pelák O, Stuchlý J, Król L, Hubacek P, Keslová P, Sedláček P, Formánková R, Starý J, Hrušák O, Kalina T. Appearance of CMV specific T-cells predicts fast resolution of viremia post hematopoietic Stem cell transplantation. Cytometry B Clin Cytom 2015: n/a-n/a
   PubMedGoogle Scholar
• Lacey SF, Gallez-Hawkins G, Crooks M, Martinez J, Senitzer D, Forman SJ, Spielberger R, Zaia JA, Diamond DJ. Characterization of cytotoxic function of CMV-pp65-specific CD8+ T-lymphocytes identified by HLA tetramers in recipients and donors of stem-cell transplants. Transplantation 2002; 74:722-32; PMID:12352893; http://dx.doi.org/10.1097/00007890-200209150-00023
   PubMed Web of Science ®Google Scholar
• Clari MÁ, Muñoz-Cobo B, Solano C, Benet I, Costa E, Remigia MJ, Bravo D, Amat P, Navarro D. Performance of the QuantiFERON-cytomegalovirus (CMV) assay for detection and estimation of the magnitude and functionality of the CMV-specific gamma interferon-producing CD8(+) T-cell response in allogeneic stem cell transplant recipients. Clin Vaccine Immunol 2012; 19:791-6; http://dx.doi.org/10.1128/CVI.05633-11
   PubMed Web of Science ®Google Scholar
• Tey SK, Kennedy GA, Cromer D, Davenport MP, Walker S, Jones LI, Crough T, Durrant ST, Morton JA, Butler JP, et al. Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV® assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications. PloS One 2013; 8:e74744; PMID:24146744; http://dx.doi.org/10.1371/journal.pone.0074744
   PubMed Web of Science ®Google Scholar
• Harris AE, Styczynski J, Bodge M, Mohty M, Savani BN, Ljungman P. Pretransplant vaccinations in allogeneic stem cell transplantation donors and recipients: an often-missed opportunity for immunoprotection? Bone Marrow Transplantation 2015; 50:899-903; PMID:25798674; http://dx.doi.org/10.1038/bmt.2015.49
   PubMed Web of Science ®Google Scholar
• Goardon N, Marchi E, Atzberger A, Quek L, Schuh A, Soneji S, Woll P, Mead A, Alford KA, Rout R, et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 2011; 19:138-52; PMID:21251617; http://dx.doi.org/10.1016/j.ccr.2010.12.012
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA, Boeckh MJ, Wilck MB, Langston AA, Chu AH, Wloch MK, Guterwill DF, Smith LR, Rolland AP, Kenney RT. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012; 12:290-9; PMID:22237175; http://dx.doi.org/10.1016/S1473-3099(11)70344-9
   PubMed Web of Science ®Google Scholar
• Nakamura R, Rosa CL, Longmate J, Drake J, Slape C, Zhou Q, Lampa MG, O'Donnell M, Cai JL, Farol L, et al. Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial. Lancet Haematol 2016; 3:e87-98; PMID:26853648; http://dx.doi.org/10.1016/S2352-3026(15)00246-X
   PubMed Web of Science ®Google Scholar
• Doubrovina E, Oflaz-Sozmen B, Prockop SE, Kernan NA, Abramson S, Teruya-Feldstein J, Hedvat C, Chou JF, Heller G, Barker JN, et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy proven EBV+ lymphomas after allogeneic hematopoietic cell transplants. Blood 2012; 119:2644-56; PMID:22138512; http://dx.doi.org/10.1182/blood-2011-08-371971
   PubMed Web of Science ®Google Scholar
• Cobbold M, Khan N, Pourgheysari B, Tauro S, McDonald D, Osman H, Assenmacher M, Billingham L, Steward C, Crawley C, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005; 202:379-86; PMID:16061727; http://dx.doi.org/10.1084/jem.20040613
   PubMed Web of Science ®Google Scholar
• Blyth E, Clancy L, Simms R, Ma CK, Burgess J, Deo S, Byth K, Dubosq MC, Shaw P, Micklethwaite KP, et al. Donor-derived CMV specific T-cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood 2013; 121:3745-58; PMID:23435462; http://dx.doi.org/10.1182/blood-2012-08-448977
   PubMed Web of Science ®Google Scholar
• Chen F, Peniket A, Tholouli E, Bloor A. CMV-specific T-cell therapy improves immune reconstitution following unrelated donor HSCT: results of a randomized controlled trial. Biol Blood Marrow Transplantation 2014; 22:782-95
   Google Scholar
• Peggs KS, Tholouli E, Chakraverty R, Nikolousis E. CMV∼ impact: results of a randomized controlled trial of immuno-prophylactic adoptive cellular therapy following sibling donor allogeneic HSCT. Blood 2014; 124(21): 1109.
   Google Scholar
• Feuchtinger T, Opherk K, Bethge WA, Topp MS, Schuster FR, Weissinger EM, Mohty M, Or R, Maschan M, Schumm M, et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 2010; 116:4360-7; PMID:20625005; http://dx.doi.org/10.1182/blood-2010-01-262089
   PubMed Web of Science ®Google Scholar
• Uhlin M, Gertow J, Uzunel M, Okas M, Berglund S, Watz E, Brune M, Ljungman P, Maeurer M, Mattsson J. Rapid salvage treatment with virus-specific T-cells for therapy-resistant disease. Clin Infect Dis 2012; 55(8):1064-73; PMID:22806594
   PubMed Web of Science ®Google Scholar
• Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH, Kapoor N, Pai SY, Rowley SD, Kebriaei P, et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 2013; 121:5113-23; PMID:23610374; http://dx.doi.org/10.1182/blood-2013-02-486324
   PubMed Web of Science ®Google Scholar
• Withers B, Blyth E, Clancy L, Burgess J, Simms R, Micklethwaite K, Gottlieb D. Third-party donor virus-specific T Cells are efficacious in the treatment of refractory viral infection following allogeneic HSCT, but may not persist post-infusion. Blood 2015; 126:623
   Web of Science ®Google Scholar
• Bleakley M, Heimfeld S, Loeb KR, Jones LA, Chaney C, Seropian S, Gooley TA, Sommermeyer F, Riddell SR, Shlomchik WD. Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts. J Clin Invest 2015; 125:2677-89; PMID:26053664; http://dx.doi.org/10.1172/JCI81229
   PubMed Web of Science ®Google Scholar
• Triplett BM, Shook DR, Eldridge P, Li Y, Kang G, Dallas M, Hartford C, Srinivasan A, Chan WK, Suwannasaen D, et al. Rapid memory T-cell reconstitution recapitulating CD45RA-depleted haploidentical transplant graft content in patients with hematologic malignancies. Bone Marrow Transplantation 2015; 50:968-77; PMID:25665048; http://dx.doi.org/10.1038/bmt.2014.324
   PubMed Web of Science ®Google Scholar
• Maschan M, Shelikhova L, Ilushina M, Kurnikova E, Boyakova E, Balashov D, Persiantseva M, Skvortsova Y, Laberko A, Muzalevskii Y, et al. TCR-α/β and CD19 depletion and treosulfan-based conditioning regimen in unrelated and haploidentical transplantation in children with acute myeloid leukemia. Bone Marrow Transplantation 2016; 51(5):668-74
   PubMed Web of Science ®Google Scholar
• Vago L, Oliveira G, Bondanza A, Noviello M, Soldati C, Ghio D, Brigida I, Greco R, Lupo Stanghellini MT, Peccatori J, et al. T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantation. Blood 2012; 120:1820-30; PMID:22709689; http://dx.doi.org/10.1182/blood-2012-01-405670
   PubMed Web of Science ®Google Scholar
• Tey SK, Dotti G, Rooney CM, Heslop HE, Brenner MK. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplantation 2007; 13:913-24; PMID:17640595; http://dx.doi.org/10.1016/j.bbmt.2007.04.005
   PubMed Web of Science ®Google Scholar
• Guinan EC, Boussiotis VA, Neuberg D, Brennan LL, Hirano N, Nadler LM, Gribben JG. Transplantation of anergic histoincompatible bone marrow allografts. N Eng J Med 1999; 340:1704-14; PMID:10352162; http://dx.doi.org/10.1056/NEJM199906033402202
   PubMed Web of Science ®Google Scholar
• Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, DeFor T, Levine BL, June CH, Rubinstein P, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011; 117:1061-70; PMID:20952687; http://dx.doi.org/10.1182/blood-2010-07-293795
   PubMed Web of Science ®Google Scholar
• Green ML, Leisenring WM, Xie H, Walter RB, Mielcarek M, Sandmaier BM, Riddell SR, Boeckh MJ. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood 2013; 122:1316-24; PMID:23744585; http://dx.doi.org/10.1182/blood-2013-02-487074
   PubMed Web of Science ®Google Scholar
• Elmaagacli AH, Steckel NK, Koldehoff M, Hegerfeldt Y, Trenschel R, Ditschkowski M, Christoph S, Gromke T, Kordelas L, Ottinger HD, et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood 2011; 118:1402-12; PMID:21540462; http://dx.doi.org/10.1182/blood-2010-08-304121
   PubMed Web of Science ®Google Scholar
• Behrendt CE, Rosenthal J, Bolotin E, Nakamura R, Zaia J, Forman SJ. Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy. Biol Blood Marrow Transplantation 2009; 15:54-60; PMID:19135943; http://dx.doi.org/10.1016/j.bbmt.2008.10.023
   PubMed Web of Science ®Google Scholar
• Ito S, Pophali P, CO W, Koklanaris EK, Superata J, Fahle GA, Childs R, Battiwalla M, Barrett AJ. CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML. Bone Marrow Transplantation 2013; 48:1313-6; PMID:23562969; http://dx.doi.org/10.1038/bmt.2013.49
   PubMed Web of Science ®Google Scholar
• Jang JE, Kim SJ, Cheong JW, Hyun SY, Kim YD, Kim YR, Kim JS, Min YH. Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia. Annals Hematol 2015; 94:275-82; PMID:25135450; http://dx.doi.org/10.1007/s00277-014-2190-1
   PubMed Web of Science ®Google Scholar
• Ramanathan M, Teira P, Battiwalla M, Barrett J, Ahn KW, Chen M, Green J, Laughlin M, Lazarus HM, Marks D, et al. Impact of early CMV reactivation in cord blood stem cell recipients in the current era. Bone Marrow Transplantation 2016; 51(8):1113-20; PMID:27042847
   PubMed Web of Science ®Google Scholar